Charles Schwab Investment Management Inc. Has $708,000 Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB)

Charles Schwab Investment Management Inc. increased its stake in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 42.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 748,718 shares of the biotechnology company’s stock after buying an additional 222,771 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.44% of Seres Therapeutics worth $708,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in MCRB. Providence Wealth Advisors LLC lifted its position in Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 25,250 shares during the period. Point72 DIFC Ltd acquired a new position in shares of Seres Therapeutics in the 2nd quarter valued at approximately $64,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Seres Therapeutics during the 2nd quarter worth approximately $92,000. Finally, Vontobel Holding Ltd. acquired a new stake in shares of Seres Therapeutics during the 3rd quarter worth approximately $374,000. Institutional investors own 59.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on MCRB. Canaccord Genuity Group restated a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research note on Thursday, November 14th. JPMorgan Chase & Co. lowered Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. StockNews.com downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 27th. Finally, Chardan Capital reissued a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a report on Wednesday, November 13th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Stock Down 2.3 %

Shares of MCRB opened at $0.86 on Thursday. The stock has a market cap of $146.83 million, a PE ratio of -3.74 and a beta of 2.07. Seres Therapeutics, Inc. has a 12-month low of $0.54 and a 12-month high of $2.05. The business has a 50-day simple moving average of $0.79 and a two-hundred day simple moving average of $0.89.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.